{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Frey SE"],"funding":["HHS","NCATS NIH HHS","NIAID NIH HHS"],"pagination":["126702"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12096342"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["47"],"pubmed_abstract":["<h4>Introduction</h4>While it remains impossible to predict the timing of the next influenza pandemic, novel avian influenza A viruses continue to be considered a significant threat.<h4>Methods</h4>A Phase II study was conducted in healthy adults aged 18-64 years to assess the safety and immunogenicity of two intramuscular doses of pre-pandemic 2017 influenza A(H7N9) inactivated vaccine administered 21 days apart. Participants were randomized (n = 105 in each of Arms 1-3) to receive 3.75 μg, 7.5 μg or 15 μg of hemagglutinin (HA) with MF59® adjuvant, or 15 μg of HA unadjuvanted vaccine (n = 57, Arm 4).<h4>Results</h4>The three MF59 adjuvanted vaccines and the 15 μg unadjuvanted vaccine were safe and well-tolerated. Little antibody activity was detected against the A(H7N9) vaccine antigen af"],"journal":["Vaccine"],"pubmed_title":["Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®."],"pmcid":["PMC12096342"],"funding_grant_id":["UL1 TR002243","HHSN272201300019C","UM1 AI148685","HHSN27220139921I","HHSN272201300023I","HHSN27200015","HHSN272201300021I","75N93021C00012","HHSN272201300016C","HHSN272201300015C","HHSN272201300019I","HHSN272201300023C","HHSN272201300016I","HHSN272201300015I"],"pubmed_authors":["Atmar RL","Abate G","Paulsen G","Rupp R","Goepfert P","Creech CB","Weiss J","Frey SE","Brady R","Wegel A","Roberts PC","El Sahly HM","Jackson L"],"additional_accession":[]},"is_claimable":false,"name":"Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®.","description":"<h4>Introduction</h4>While it remains impossible to predict the timing of the next influenza pandemic, novel avian influenza A viruses continue to be considered a significant threat.<h4>Methods</h4>A Phase II study was conducted in healthy adults aged 18-64 years to assess the safety and immunogenicity of two intramuscular doses of pre-pandemic 2017 influenza A(H7N9) inactivated vaccine administered 21 days apart. Participants were randomized (n = 105 in each of Arms 1-3) to receive 3.75 μg, 7.5 μg or 15 μg of hemagglutinin (HA) with MF59® adjuvant, or 15 μg of HA unadjuvanted vaccine (n = 57, Arm 4).<h4>Results</h4>The three MF59 adjuvanted vaccines and the 15 μg unadjuvanted vaccine were safe and well-tolerated. Little antibody activity was detected against the A(H7N9) vaccine antigen af","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-07-15T21:33:19.045Z","creation":"2026-07-09T10:14:46.613Z"},"accession":"S-EPMC12096342","cross_references":{"pubmed":["39798434"],"doi":["10.1016/j.vaccine.2024.126702"]}}